Jurgi Camblong Sells 24,381 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 24,381 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $6.29, for a total transaction of $153,356.49. Following the completion of the transaction, the chairman directly owned 3,512,822 shares in the company, valued at $22,095,650.38. This represents a 0.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total value of $132,600.00.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total value of $44,540.00.

SOPHiA GENETICS Trading Down 0.4%

Shares of SOPH stock opened at $5.55 on Thursday. The stock’s fifty day moving average is $5.44 and its two-hundred day moving average is $5.09. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The firm has a market capitalization of $465.59 million, a P/E ratio of -10.67 and a beta of 0.96. SOPHiA GENETICS SA has a fifty-two week low of $2.92 and a fifty-two week high of $6.77.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%. Research analysts expect that SOPHiA GENETICS SA will post -0.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on SOPH shares. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright initiated coverage on SOPHiA GENETICS in a report on Monday, July 20th. They issued a “buy” rating and a $12.00 price target for the company. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds have recently modified their holdings of the company. Perkins Capital Management Inc. purchased a new position in SOPHiA GENETICS during the fourth quarter worth about $49,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.